ARA-290 (Cibinetide): An Erythropoietin-Derived Peptide

ARA 290 is a short peptide of 11 amino acids. Its nonproprietary name is cibinetide. It is modeled on one surface of erythropoietin (EPO), a hormone best known for driving red blood cell production. EPO has long been linked to two jobs. The first is making red blood cells through the classical EPO receptor. The second is a set of cell-protecting and anti-inflammatory effects seen in preclinical models. These are thought to work through a different receptor complex. ARA 290 was designed to split the two apart. That makes it a useful case study in peptide design based on protein structure. It also shows how a receptor idea can shape a research program while it is still debated.

This profile stays with structure, receptor biology and preclinical evidence. Incredible Peptides does not supply ARA 290. You can find the compounds we do carry in the research peptides category.

EPO and its two proposed receptor systems

EPO is a glycoprotein cytokine with 165 residues. It folds into a bundle of four helices, labeled A to D. Its blood-forming (hematopoietic) activity runs through the EPO receptor (EPOR). EPOR is a type I cytokine receptor. Crystal structure work showed that one EPO molecule binds two EPOR chains. Together they form a homodimer, a pair of matching chains, that switches on JAK2 signaling. The surfaces of EPO that touch the receptor lie mainly on helices A, C and D.

From the late 1990s, a body of animal and cell-culture work found that EPO does more. It also seemed to protect neurons, heart muscle cells and other cells under stress. That stress could be ischemic, toxic or inflammatory. These effects often needed higher concentrations than red cell production did. So researchers proposed a second receptor with a weaker grip on EPO. Some chemically changed forms of EPO were tested in rodent models. Two notable ones were asialo-EPO and carbamylated EPO. Reports said they kept their protective effect but no longer boosted red cell production. This made the case stronger that the two jobs could be split.

The innate repair receptor idea

In 2004, Brines and colleagues put forward a new idea. They proposed that EPO’s tissue-protecting effects depend on a mixed receptor complex. In it, EPOR pairs with the β common receptor subunit (βcR, CD131). βcR is the signaling chain shared by the receptors for interleukin-3, interleukin-5 and GM-CSF. In their mouse tests, EPO’s protective effects were missing in animals that lacked βcR. The complex was later named the innate repair receptor. The name reflects the idea that stressed tissue makes more of it locally.

The idea has been challenged. Finding EPOR in tissue outside the blood system has proved hard in the lab. Elliott and colleagues showed why that matters. Many commercial anti-EPOR antibodies are not specific enough for reliable detection. The direct physical pairing of EPOR with βcR has also been hard to show. So has its stoichiometry, meaning how many copies of each chain join the complex. The classical homodimer was much easier to pin down. Other receptors have been proposed for EPO’s non-blood actions too. So it is fair to say ARA 290 was designed to engage a proposed receptor. Its structure is not settled.

From helix B to an 11-residue peptide

The EPOR homodimer touches helices A, C and D. That leaves helix B facing the surrounding water. In 2008, Brines and colleagues reasoned that this water-facing surface might carry the tissue-protecting activity. So they designed a short, straight-chain peptide from it. They called it the helix B surface peptide (HBSP). The goal was to copy how the key helix B residues sit in space. They did not simply copy one unbroken stretch of the sequence. In their cell and rodent tests, HBSP was protective. It did not drive red cell production.

Sequence and chemistry

ARA 290 is HBSP with a pyroglutamate at the N-terminus. The sequence is usually given as pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser. Its formula is C₅₁H₈₄N₁₆O₂₁, and its average molecular weight is about 1257.3 g/mol. Pyroglutamate is a glutamine that has closed into a ring. It caps the N-terminus and takes away a positive charge. That cap also guards the peptide against aminopeptidases, the enzymes that chew from that end. Native peptides use the same trick, among them thyrotropin-releasing hormone.

The sequence is strongly hydrophilic, meaning it mixes well with water. Three glutamate residues and the C-terminal carboxylate outweigh the single arginine. So the peptide carries a net negative charge at neutral pH. That is why it comes off early in reversed-phase HPLC. There is also a structural question. A short helical piece taken out of its parent protein is unlikely to hold a steady helix in water. For that reason, the structural basis of its activity is still a matter of inference. Early elution matters for purity work as well. Polar by-products of synthesis can crowd the same part of the chromatogram. Our quality testing overview for research peptides covers this kind of issue.

Analytical points

A few features matter when you characterize this peptide. The capped N-terminus blocks Edman sequencing. So identity rests on mass spectrometry and fragmentation data. The monoisotopic mass is about 1256.6 Da. If the ring does not close fully during synthesis, you get an N-terminal glutamine variant. It is 17 Da heavier and must be told apart from the target. The Asn-Ser motif can also deamidate. That yields aspartate and isoaspartate variants about 1 Da apart. High-resolution LC-MS is the best way to track them. All of these are routine concerns in peptide quality control.

Preclinical findings and their limits

The published preclinical work on HBSP and ARA 290 covers rodent models and cultured cells. The rodent models involve ischemia-reperfusion, inflammation and neuropathy. Reports describe lower inflammatory signaling and better tissue outcomes. One finding runs through that work: the peptides do not raise hematocrit in animals. Hematocrit is the share of blood made up of red cells. That result fits their non-erythropoietic design. The developers also described the peptide as short-lived in plasma. They argued that a brief touch on the receptor could still start longer-lasting signaling.

These are animal and cell-culture results, and they have limits. Much of the literature comes from the developing group and its collaborators. The link to the EPOR/βcR complex often rests on knockout or blocking experiments. It rarely rests on direct binding measurements with a well-characterized receptor. Moving findings between models and species is not simple either. Reading on in vitro vs in vivo evidence helps put each claim in context. Our article on peptide receptor binding covers the principles involved.

ARA 290 as a structure-based design case

ARA 290 shows a design strategy worth knowing, whatever its final standing turns out to be. Start with a protein that has more than one activity. Map which surface serves which receptor. Then build a peptide that shows only one of those surfaces. Its sequence is short and well defined. Its chemistry raises familiar analytical issues, in pyroglutamate formation and in deamidation. Its receptor hypothesis is still open. For labs working with any synthetic peptide like this, identity and purity data matter as much as the hypothesis. Our page on peptide identity and purity testing explains what that paperwork should include.

References

1. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proceedings of the National Academy of Sciences USA, 2004.
2. Brines M, Patel NSA, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences USA, 2008.
3. Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science, 2004.
4. Elliott S, Busse L, Bass MB, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood, 2006.